Can't Miss Webinar—Lupus Nephritis: The ACR Guideline in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Biologics

Researchers Find Rheumatologists Are Prescribing Methotrexate Less Often to Treat RA

Richard Quinn  |  December 8, 2015

An analysis by former ACR President James O’Dell, MD, and colleagues shows that rheumatologists may be moving too quickly from methotrexate therapy to biologics when treating patients with RA…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:BiologicsMethotrexaterheumatologist

Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease

Will Boggs, MD  |  December 8, 2015

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) commonly develop skin lesions related to anti-tumor necrosis factor (anti-TNF) medications, according to a retrospective study. “We were most surprised by the relatively high percentage (30%) of patients developing skin problems while being treated with anti-TNF agents,” Dr. Isabelle Cleynen from KU Leuven, Belgium, tells Reuters…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Anti-TNFinflammatory bowel diseaseinfliximabPsoriasisrashskin

2015 ACR Guideline for the Treatment of Rheumatoid Arthritis

Arthritis & Rheumatology  |  November 30, 2015

“Treat to target regardless of disease activity level” tops the list of recommendations for both early and established RA in the 2015 Guideline for the Treatment of Rheumatoid Arthritis. The guideline addresses six major topics, including DMARDs, glucocorticoids and biologics, and includes 74 recommendations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients together…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:ACR/AHRP Annual MeetingArthritis & RheumatologyBiologicsDisease-modifying antirheumatic drugs (DMARDs)Research

Sjögrens Syndrome: The Need to Bridge Patient Symptoms & Objective Findings

Sjögrens Syndrome: The Need to Bridge Patient Symptoms & Objective Findings

Robert I. Fox, MD, PhD, & Carla M. Fox, RN  |  November 17, 2015

Despite a generation of advances in molecular biology, a huge gap exists between the Sjögren’s syndrome (SS) patient’s description of their symptoms and the objective findings. Current issues include: Many SS patients are misclassified as either rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), even within rheumatology clinics. Frequently, the sickest SS patients with extraglandular…

Filed under:ConditionsOther Rheumatic ConditionsResearch RheumSjögren’s Disease Tagged with:ClinicalDiagnosispatient careResearchSjogren'ssymptomTreatment

Improve RA Care with Vitamin D

Dewan K. Fahima, DO, & Rafah Salloum, MD  |  November 16, 2015

Background Autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythema­tous, occur when the body attacks its own tissue because it cannot differentiate between self and non-self. This is mainly through deregulation of the immune system. Vitamin D has been known to play a critical role in bone mineralization and bone health. Activated vitamin…

Filed under:ConditionsPractice SupportRheumatoid Arthritis Tagged with:patient carePractice ManagementRARheumatoid arthritisTreatmentVitamin D

Rheumatologist Steven S. Overman Reflects on His Last Day of Practice, Future of Specialty

Steven S. Overman, MD, MPH • illustrations by Alice C. Gray  |  November 16, 2015

I am a few weeks post-retirement. Having written thank you notes and completed urgent home projects, I swing in a hammock at our currently fire-threatened cabin north of Winthrop, Wash., and reflect. I feel like a young boy while freely flipping pages of a hand-scribed picture book, The Principles of Uncertainty, by Maira Kalman. She…

Filed under:Practice SupportProfiles Tagged with:Profileretirementrheumatologistrheumatology practice

2015 ACR Guideline for the Treatment of Rheumatoid Arthritis Now Available

American College of Rheumatology  |  November 10, 2015

The American College of Rheumatology (ACR) announced the availability of its 2015 Guideline for the Treatment of Rheumatoid Arthritis (RA) during the 2015 ACR/ARHP Annual Meeting in San Francisco. An early draft of the recommendations was presented at last year’s meeting in Boston, and the final recommendations are now available on the ACR website. The…

Filed under:ConditionsFrom the CollegeRheumatoid Arthritis

Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer

Will Boggs, MD  |  November 4, 2015

NEW YORK (Reuters Health)—Methotrexate appears to increase the risk of recurrent nonmelanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA), according to a retrospective study. “We have known for some time that several of the immunosuppressive agents used to treat RA and inflammatory bowel disease (IBD) are also associated with an increased risk of…

Filed under:Drug Updates Tagged with:Cancerinflammatory bowel diseaseMethotrexatenonmelanoma skin cancer (NMSC)Rheumatiod arthritis

German Registry Evaluates Systemic Psoriasis Treatments

Michele B. Kaufman, PharmD, BCGP  |  November 4, 2015

The German Psoriasis Registry, PsoBest, found conventional systemic and biologic drugs for psoriasis demonstrated relative safety from serious adverse events in patients between January 2008–December 2012…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicsGermanyMethotrexatePsoriasis

Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA

Michele B. Kaufman, PharmD, BCGP  |  October 14, 2015

In a global Phase 3 trial, subcutaneous secukinumab proved safe and effective in patients with psoriatic arthritis. Also, a version of aspartyl-alanyl diketopiperazine, a biologic for knee OA, has entered Phase 3 trials…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone DisordersOther Rheumatic Conditions Tagged with:analgesicKnee Osteoarthritis (OA)Painpsoriatic arthritissecukinumab

  • « Previous Page
  • 1
  • …
  • 55
  • 56
  • 57
  • 58
  • 59
  • …
  • 77
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences